Overview
Sponsor-declared trial summary
Phase
Human pharmacology (Phase I) - Bioequivalence study
Status
Ended
Participants planned
24
Countries
1
Sites
1
Alzheimer’s disease
Key facts
- Sponsor
- Laboratorios Alter S.A.
- Participant type
- Healthy volunteers
- Age range
- 18-64 years
- Gender
- Male and Female
- Therapeutic area
- Psychiatry and Psychology [F] - Mental Disorders [F03]
- Trial duration
- 24 Oct 2025 → 18 Dec 2025
- Decision date (initial)
- 2025-10-09
- Transition trial
- No
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- No
Trial design
CTIS Part I — objectives, methods, condition coding
Conditions and MedDRA coding
Alzheimer’s disease
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Laboratorios Alter S.A.
- Sponsor organisation
- Laboratorios Alter S.A.
- Address
- Calle De Mateo Inurria 30
- City
- Madrid
- Postcode
- 28036
- Country
- Spain
Scientific contact point
- Organisation
- Laboratorios Alter S.A.
- Contact name
- Carmen Morillo Alonso
Public contact point
- Organisation
- Laboratorios Alter S.A.
- Contact name
- Carmen Morillo Alonso
Locations
1 EU/EEA country · 1 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Spain | Ended | 24 | 1 |
| Rest of world | — | 0 | — |
Investigational sites
Country notifications
Trial-start, recruitment-start, end and early-termination notifications submitted per Member State
| Country | Trial start | Trial end | Recruitment start | Recruitment end | Early termination |
|---|---|---|---|---|---|
| Spain | 2025-10-24 | 2025-12-18 | 2025-10-27 | 2025-11-12 |
Application history
1 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2025-09-18 | Spain | Acceptable 2025-10-08
|
2025-10-09 |